Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Celator Pharmaceuticals
Sponsor:
Collaborator:
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Celator Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01696084
First received: September 26, 2012
Last updated: July 25, 2014
Last verified: July 2014
  Purpose

To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.


Condition Intervention Phase
High Risk Acute Myeloid Leukemia
Drug: CPX-351
Drug: 7+3 (cytarabine and daunorubicin)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML

Resource links provided by NLM:


Further study details as provided by Celator Pharmaceuticals:

Primary Outcome Measures:
  • Overall Survival [ Time Frame: Dec 2016 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: November 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A (CPX-351)
Study drug will be given intravenously at 100u/m2 on days 1, 3 and 5 by approximately 90 minute infusion.
Drug: CPX-351
Active Comparator: Arm B (7+3)
Therapy will be administered intravenously with 100mg/m2/day of cytarabine administered by continuous infusion for 7 days and 60mg/m2 of daunorubicin given on days 1, 2 and 3.
Drug: 7+3 (cytarabine and daunorubicin)
Other Name: cytarabine and daunorubicin

  Eligibility

Ages Eligible for Study:   60 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to understand and voluntarily give informed consent
  • Age 60-75 years at the time of diagnosis of AML
  • Pathological diagnosis of AML according to WHO criteria (with at least 20% blasts in the peripheral blood or bone marrow)
  • Confirmation of:

    • Therapy related AML: t-AML must have a documented history of prior cytotoxic therapy or ionizing radiotherapy for an unrelated disease
    • AML with a history of myelodysplasia: MDSAML must have bone marrow documentation of prior MDS
    • AML with a history of CMMoL: CMMoLAML must have bone marrow documentation of prior CMMoL
    • De novo AML with karyotypic abnormalities characteristic of MDS: de novoAML must have cytogenetics with abnormalities per WHO.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Able to adhere to the study visit schedule and other protocol requirements
  • Laboratory values fulfilling the following:

    • Serum creatinine < 2.0 mg/dL
    • Serum total bilirubin < 2.0 mg/dL, patients with Gilbert's Syndrome should contact the medical monitor
    • Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN Note: If elevated liver enzymes, above the ULN, are related to disease; contact medical monitor to discuss.
  • Cardiac ejection fraction ≥ 50% by echocardiography or MUGA
  • Patients with second malignancies in remission may be eligible if there is clinical evidence of disease stability for a period of greater than 6 months off cytotoxic chemotherapy, documented by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible.
  • Except for CMMoL, patients with history of myeloproliferative neoplasms (MPN) (defined as a history of essential thrombocytosis or polycythemia vera, or idiopathic myelofibrosis prior to the diagnosis of AML) or combined MDS/MPN are not eligible.
  • Acute promyelocytic leukemia [t(15;17)] or favorable cytogenetics, including t(8;21) or inv16 if known at the time of randomization.
  • Clinical evidence of active CNS leukemia
  • Patients with active (uncontrolled, metastatic) second malignancies are excluded.
  • Prior treatment intended for induction therapy of AML; only hydroxyurea is permitted for control of blood counts. For example, a patient with MDS that changes HMA dose and schedule after the diagnosis of AML is excluded. AML-type therapy, such as cytarabine alone (>1g/m2/day) or cytarabine plus an anthracycline as well as prior HSCT are also excluded.
  • Administration of any therapy for MDS (conventional or investigational) must be completed by 2 weeks prior to of the first dose of study drug; in the event of rapidly proliferative disease use of hydroxyurea is permitted until 24 hours before the start of study treatment. Toxicities associated with prior MDS therapy must have recovered to grade 1 or less prior to start of treatment.
  • Any major surgery or radiation therapy within four weeks.
  • Patients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent).
  • Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent obtaining informed consent
  • Patients with myocardial impairment of any cause (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging)
  • Active or uncontrolled infection. Patients with an infection receiving treatment (antibiotic, antifungal or antiviral treatment) may be entered into the study but must be afebrile and hemodynamically stable for ≥72 hrs.
  • Current evidence of invasive fungal infection (blood or tissue culture); patients with recent fungal infection must have a subsequent negative cultures to be eligible; known HIV (new testing not required) or evidence of active hepatitis B or C infection (with rising transaminase values)
  • Hypersensitivity to cytarabine, daunorubicin or liposomal products
  • History of Wilson's disease or other copper-metabolism disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01696084

Contacts
Contact: Arthur C Louie, MD 609-243-0123 alouie@celatorpharma.com
Contact: Kim H Paulsen 609-243-6235 kpaulsen@celatorpharma.com

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35294
Principal Investigator: Harry Erba, MD         
United States, California
UCLA Recruiting
Los Angeles, California, United States, 90095
Principal Investigator: Gary Schiller, MD         
University of CA San Diego Recruiting
San Diego, California, United States, 92037-0706
Principal Investigator: Matthew Wieduwilt, MD, PhD         
Stanford University Recruiting
Stanford, California, United States, 94305
Principal Investigator: Bruno Medeiros, MD         
United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06510
Principal Investigator: Nikolai Podoltsev, MD         
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32611
Principal Investigator: Maxim Norkin, MD         
H. Lee Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Principal Investigator: Jeffrey Lancet, MD         
United States, Georgia
Northside Hospital Recruiting
Atlanta, Georgia, United States, 30342
Principal Investigator: Scott Solomon, MD         
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: Wendy Stock, MD         
Northwestern University Recruiting
Chicago, Illinois, United States, 60208
Principal Investigator: Olga Frankfurt, MD         
Rush University Medical Center Recruiting
Chicago, Illinois, United States, 60612
Principal Investigator: Melissa Larson, MD         
United States, Indiana
Franciscan St. Francis Health Recruiting
Indianapolis, Indiana, United States, 46237
Principal Investigator: Eric Rubenstein, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Principal Investigator: Tara Lin, MD         
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Principal Investigator: Richard Stone, MD         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Principal Investigator: Dale L. Bixby, M.D., Ph.D         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Principal Investigator: Erica D Warlick, MD         
United States, Missouri
University of Missouri Recruiting
Columbia, Missouri, United States, 65211
Principal Investigator: Carl Freter, MD         
Washington University Recruiting
St. Louis, Missouri, United States, 63110
Principal Investigator: Geoffrey Uy, MD         
United States, New Hampshire
Dartmouth Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Principal Investigator: Marc Gautier, MD         
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Principal Investigator: Anthony Mato, MD         
United States, New York
Montefiore Medical Center Recruiting
Bronx, New York, United States, 10467
Principal Investigator: Stefan Barta, MD         
North Shore LIJ Health System Recruiting
Long Island, New York, United States
Principal Investigator: Jon E. Kolitz, MD         
Columbia University Recruiting
New York, New York, United States, 10032
Principal Investigator: Todd L Rosenblat, MD         
Cornell U, Weill Medical College Recruiting
New York, New York, United States, 10065
Principal Investigator: Eric J. Feldman, MD         
New York Medical College Recruiting
Valhalla, New York, United States, 10595
Principal Investigator: Karen Seiter, MD         
United States, North Carolina
University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27599-1651
Principal Investigator: Matthew Foster, MD         
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Principal Investigator: Arati Rao, MD         
Wake Forest University Health Services Recruiting
Winston-Salem, North Carolina, United States, 27157
Principal Investigator: Bayard Powell, MD         
United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Principal Investigator: Laura F Newell, MD         
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Principal Investigator: John Godwin, MD         
United States, Pennsylvania
UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15219
Principal Investigator: Michael Boyiadzis, MD         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Principal Investigator: Robert Stuart, MD         
United States, Tennessee
Vanderbilt University Recruiting
Nashville, Tennessee, United States, 37232
Principal Investigator: Stephen A. Strickland, MD         
Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
Principal Investigator: Jesus Berdeja         
United States, Texas
Baylor Research Insitute Recruiting
Dallas, Texas, United States, 75246
Principal Investigator: Moshe Levy, MD         
M.D. Anderson Cancer Center Recruiting
Houston, Texas, United States, 770303
Principal Investigator: Jorge Cortes, MD         
United States, Washington
Fred Hutchinson Cancer Research Center Recruiting
Seattle, Washington, United States, 98109
Principal Investigator: John Pagel, MD, PhD         
United States, Wisconsin
Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Principal Investigator: Ehab Attalah, MD         
Canada, Alberta
University of Alberta Hospital Recruiting
Edmonton, Alberta, Canada, T6G 2C8
Principal Investigator: Irwindeep Sandhu, MD         
Canada, British Columbia
British Columbia Cancer Center Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Principal Investigator: Donna Hogge, MD         
Canada, Ontario
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G2M9
Principal Investigator: Karen Yee, MD         
Canada, Quebec
Hopital Maisonneuve-Rosemont Recruiting
Montreal, Quebec, Canada
Principal Investigator: Julie Bergeron, MD         
Sponsors and Collaborators
Celator Pharmaceuticals
The Leukemia and Lymphoma Society
  More Information

No publications provided

Responsible Party: Celator Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01696084     History of Changes
Other Study ID Numbers: CLTR0310-301
Study First Received: September 26, 2012
Last Updated: July 25, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Celator Pharmaceuticals:
AML
Acute Myeloid Leukemia
high risk AML
secondary AML
AML in elderly

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Neoplasms by Histologic Type
Neoplasms
Cytarabine
Daunorubicin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 26, 2014